...
首页> 外文期刊>Circulation journal >Phosphoglucomutase Activity as a Novel Biomarker in Patients With Acute Myocardial Infarction
【24h】

Phosphoglucomutase Activity as a Novel Biomarker in Patients With Acute Myocardial Infarction

机译:磷酸葡萄糖突变酶活性作为急性心肌梗死患者的新型生物标志物

获取原文
           

摘要

Background: Phosphoglucomutase (PGM), a key enzyme in cellular glucose utilization and energy homeostasis, has been reported to show a relationship with oxidative stress. However, the clinical importance of PGM activity has not been investigated in patients with ischemic heart disease (IHD). The aim of the present pilot study was to clarify whether PGM activity has potential as a cardiovascular risk predictor in patients with IHD. Methods and Results: The levels of serum PGM activity in 237 patients with IHD (63 patients with acute myocardial infarction (AMI) and 174 patients with stable effort angina pectoris (EAP)) were evaluated. PGM activity was compared with levels of various myocardial, thrombosis, and inflammatory biomarkers on admission. PGM activity in the AMI group was significantly increased relative to that in the EAP group on admission (AMI, 55.5μmol·min–1·L–1 (U/L); EAP, 14.4U/L (P<0.001)), and was observed to increase in parallel with well-established myocardial markers (P<0.001). Moreover, PGM activity and the lipid, thrombosis, and inflammatory biomarkers in the AMI group were higher than those in the EAP group. Conclusions: PGM activity increased with levels of myocardial, thrombosis, and inflammatory biomarkers in patients with AMI, and might be useful in diagnostic applications during the acute phase in patients with AMI. ( Circ J 2012; 76: 2197–2203)
机译:背景:磷酸葡萄糖突变酶(PGM)是细胞葡萄糖利用和能量稳态中的关键酶,已显示出与氧化应激的关系。但是,尚未在患有缺血性心脏病(IHD)的患者中研究过PGM活性的临床重要性。本试验研究的目的是阐明PGM活性在IHD患者中是否具有潜在的心血管危险预测因子。方法和结果:评估了237例IHD患者(63例急性心肌梗死(AMI)和174例稳定努力型心绞痛(EAP)患者)的血清PGM活性。将PGM活性与入院时各种心肌,血栓形成和炎症生物标志物的水平进行比较。相对于EAP组,AMI组的PGM活性显着增加(AMI,55.5μmol·min –1 ·L –1 (U / L) ; EAP,14.4U / L(P <0.001)),并且与成熟的心肌标志物平行升高(P <0.001)。此外,AMI组的PGM活性以及脂质,血栓形成和炎症生物标志物均高于EAP组。结论:PGM活性随AMI患者的心肌,血栓形成和炎性生物标志物水平而增加,可能在AMI患者急性期的诊断应用中有用。 (Circ J 2012; 76:2197-2203)

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号